Castle Biosciences Inc Overview
Industry: Diagnostics & Research
Sector: Healthcare
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary 35-GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was incorporated in 2007 and is headquartered in Friendswood, Texas. Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed wi Read MoreMavefund brings filings, fundamentals, valuation, price history and news for Castle Biosciences Inc into one research view. The sections below show what strengthens or weakens the research case.
Score
Reported Results
What the company reported, with filing details kept small.
Quarterly result summary
Revenue was $103.5M (+20% YoY). Net income/share was $0.16. Net loss was -$16.6M (-22% YoY).
Revenue
$103.5M
+20% YoY
Net income/share
$0.16
reported
Net loss
-$16.6M
-22% YoY
Adjusted EBITDA
$12.4M
reported
What changed
- Revenue +20% YoY to $103.5M.
- Net loss -22% YoY to -$16.6M.
Guidance / outlook
No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.
Earnings release
Open filing
Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.
Other recent earnings materials
SEC filing
10-Q
Jul 30, 2026
SEC filing
8-K
Jul 30, 2026
SEC filing
10-Q
May 06, 2026
SEC filing
8-K
May 06, 2026
Earnings release
Earnings release
May 06, 2026
SEC filing
10-K
Feb 26, 2026
SEC filing
8-K
Feb 26, 2026
Earnings release
Earnings release
Feb 26, 2026
SEC filing
8-K
Jan 13, 2026
SEC filing
10-Q
Nov 03, 2025
Earnings release
Earnings release
Nov 03, 2025
Prediction-grade evidence
Recent News
Company-relevant articles from sources that pass the Mave Signal relevance and reliability checks.
Castle Biosciences at canaccord growth conference: growth broadens By Investing.com
Headline from Investing.com Canada: Castle Biosciences at canaccord growth conference: growth broadens By Investing.com.
Castle Biosciences at canaccord growth conference: growth broadens
Headline from Investing.com: Castle Biosciences at canaccord growth conference: growth broadens.
CSTL Aug 2026 30.000 put (CSTL260821P00030000) interactive stock chart
Headline from Yahoo Finance Singapore: CSTL Aug 2026 30.000 put (CSTL260821P00030000) interactive stock chart.
BTIG raises Castle Biosciences stock price target on strong revenue
Headline from Investing.com: BTIG raises Castle Biosciences stock price target on strong revenue.
Earnings Per Share
Score 2.00/5
Castle Biosciences Inc earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
In
Diagnostics & Research industry
, IQVIA Holdings Inc
, Agilent Technologies Inc
, Thermo Fisher Scientific Inc
are companies with high ratings.
Return on Equity
Score 2.13/5
Castle Biosciences Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
0%
10%
20%
30%
40%
ROE
Company —
Sector Median —
Metric chart temporarily unavailable.
Net Margin
Score 2.02/5
Castle Biosciences Inc
olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
0%
10%
20%
30%
40%
Net Margin
Company —
Sector Median —
Metric chart temporarily unavailable.
Leverage
Score 3.73/5
Castle Biosciences Inc
attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as
Zoetis Inc
IQVIA Holdings Inc
Agilent Technologies Inc
, also exhibit high scores.
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
0
1
2
3
4
Leverage
Company —
Sector Median —
Metric chart temporarily unavailable.
Financial Statements
Company-reported SEC EDGAR facts organized into the three core statements.
Verified SEC statements load when this section enters view.
Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.
Financial Ratio
Yearly
Quarterly
Financial
Profitability
Growth
Cash Flow
Financial Health
Efficiency Ratios